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Abstract
Background
Children with medically complicated severe acute malnutrition (SAM) have high risk of inpa-
tient mortality. Diarrhea, carbohydrate malabsorption, and refeeding syndrome may contrib-
ute to early mortality and delayed recovery. We tested the hypothesis that a lactose-free,
low-carbohydrate F75 milk would serve to limit these risks, thereby reducing the number of
days in the stabilization phase.
Methods and findings
In a multicenter double-blind trial, hospitalized severely malnourished children were ran-
domized to receive standard formula (F75) or isocaloric modified F75 (mF75) without lac-
tose and with reduced carbohydrate. The primary endpoint was time to stabilization, as
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defined by the World Health Organization (WHO), with intention-to-treat analysis. Second-
ary outcomes included in-hospital mortality, diarrhea, and biochemical features of malab-
sorption and refeeding syndrome. The trial was registered at clinicaltrials.gov
(NCT02246296). Four hundred eighteen and 425 severely malnourished children were ran-
domized to F75 and mF75, respectively, with 516 (61%) enrolled in Kenya and 327 (39%) in
Malawi. Children with a median age of 16 months were enrolled between 4 December 2014
and 24 December 2015. One hundred ninety-four (46%) children assigned to F75 and
188 (44%) to mF75 had diarrhea at admission. Median time to stabilization was 3 days
(IQR 2–5 days), which was similar between randomized groups (0.23 [95% CI −0.13 to
0.60], P = 0.59). There was no evidence of effect modification by diarrhea at admission,
age, edema, or HIV status. Thirty-six and 39 children died before stabilization in the F75
and in mF75 arm, respectively (P = 0.84). Cumulative days with diarrhea (P = 0.27), enteral
(P = 0.42) or intravenous fluids (P = 0.19), other serious adverse events before stabilization,
and serum and stool biochemistry at day 3 did not differ between groups. The main limitation
was that the primary outcome of clinical stabilization was based on WHO guidelines, com-
prising clinical evidence of recovery from acute illness as well as metabolic stabilization evi-
denced by recovery of appetite.
Conclusions
Empirically treating hospitalized severely malnourished children during the stabilization
phase with lactose-free, reduced-carbohydrate milk formula did not improve clinical out-
comes. The biochemical analyses suggest that the lactose-free formulae may still exceed a
carbohydrate load threshold for intestinal absorption, which may limit their usefulness in the
context of complicated SAM.
Trial registration
ClinicalTrials.gov NCT02246296.
Introduction
Children with complicated severe acute malnutrition (SAM) are admitted to the hospital
because they are severely ill or unable to feed sufficiently [1]. In African hospitals, their risk of
inpatient death ranges between 10%–30% [2–4]. In contrast, children with SAM who are clini-
cally stable, i.e., without signs of illness and who have an appetite (uncomplicated SAM), are
usually treated in community-based programs and have a substantially lower mortality risk,
ranging between<1%–7% [5–7]. In hospital settings, mortality may be reduced to some extent
by adhering to World Health Organization (WHO)–recommended management [2,4,8,9], but
this may not address the full spectrum of infections and metabolic abnormalities of these seri-
ously ill children [10–12]. In the 2013 Lancet Maternal and Child Nutrition series, improving
management of SAM was identified as having the greatest likely impact on child mortality
amongst nutritional interventions [13].
Current guidelines for the nutritional management of SAM in the hospital define 3 phases
of treatment [14]: 1) the “stabilization phase,” during which children are fed a liquid diet (stan-
dard F75 [F75]) with a relatively low-protein (approximately 9 g/l) and relatively low-energy
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content (75 kcal/100 ml). F75 was designed to meet the estimated nutritional requirements to
restore physiological and metabolic functions and to prevent refeeding syndrome while medi-
cal conditions stabilize. No weight gain is expected during this phase of treatment; 2) the “tran-
sition phase,” during which higher protein and energy through either F100 formula or ready-
to-use therapeutic foods (RUTFs) are started with supplemental F75 formula; and 3) the “reha-
bilitation phase,” with an increased daily intake of F100 or RUTFs in order to achieve catch-up
growth. Once a child has stabilized and tolerates RUTFs, WHO guidelines recommend dis-
charge from hospital care, with continuation of the rehabilitation phase continued in the com-
munity [14,15].
The original F75 formulation was designed based on what was known about the pathophys-
iology of SAM at that time, before separation of treatment of complicated and uncomplicated
SAM [16]. Today’s inpatient children with complicated SAM have a very different clinical pro-
file from uncomplicated SAM treated in the community. Around 65% of calories in the F75
formula is derived from carbohydrates (maltodextrin, lactose, and sucrose). Once ingested,
disaccharides such as lactose or sucrose are hydrolyzed into monosaccharides by disacchari-
dases found at the tip of small intestinal villi. Released monosaccharides such as glucose and
galactose are then transported across the apical membrane through Na+-dependent glucose
transporters, whereas fructose is taken up through a facilitative fructose transporter [17]. How-
ever, evidence suggests that children with SAM have impaired absorption of mono- and disac-
charides, regardless of the presence of gastroenteritis [18,19]. Limited histological evidence
also shows intestinal villous atrophy [18], which is consistent with clinical signs suggestive of
carbohydrate malabsorption [20]. Thus, we hypothesized that revising the current F75 into a
modified, lactose-free, and reduced-carbohydrate F75 formulation could reduce osmotic diar-
rhea and thereby lower the number of days to complete the first phase of treatment.
Early deterioration in children with SAM may also be related to refeeding syndrome, com-
prising severe metabolic derangements driven by insulin excretion after a sudden shift from a
catabolic to an anabolic state [21]. Refeeding syndrome is characterized by hypophosphatemia,
hypokalemia, and hypomagnesemia, which may impair cardiac, pulmonary, and neurological
function and can result in (sudden) death. As protein synthesis is stimulated in anabolism,
increased production of adenosine triphosphate (ATP) leads to a higher cellular demand for
phosphate [21]. Furthermore, pancreatic insulin secretion induces the cellular uptake of glu-
cose and electrolytes, including phosphate and potassium, and hypophosphatemia is common
during nutritional rehabilitation of malnourished children and is associated with mortality
[22–24]. We also hypothesized that a reduction in carbohydrate content of the modified F75
formula could lower the risk of refeeding syndrome. Together, reformulated F75 could plausi-
bly improve early clinical outcomes among hospitalized children with SAM.
We conducted a randomized, double-blind controlled trial evaluating a modified F75 for-
mula with substantially reduced carbohydrate content and without lactose versus the currently
recommended formulation of F75 among hospitalized children with SAM in Kenya and
Malawi.
Methods
Study design and participants
The study was a randomized, double-blind controlled trial conducted at two Kenyan hospitals
(Kilifi County Hospital and Coast General Hospital, Mombasa) and one Malawian hospital
(Queen Elizabeth Central Hospital, Blantyre). All children admitted to these study hospitals
were screened for complicated SAM. The study was discussed in detail with parents or carers
of potential participants in their local language, and written informed consent was sought. In
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patients for which re-establishing feeding was urgent, initial verbal assent was sought and fol-
lowed up with written consent after treatment initiation.
Inclusion criteria were
• age 6 months to 13 years;
• SAM defined as mid-upper arm circumference (MUAC) < 11.5 cm or weight-for-height Z
score< −3 if younger than 5 years of age, BMI Z score < −3 if older than 5 years, or edema-
tous malnutrition at any age;
• being admitted to the hospital because of medical complications or failing an appetite test, as
defined by WHO guidelines [16];
• weight-for-length/height or BMI, weight-for-age, and length/height-for-age Z scores were
calculated using WHO 2006 and 2007 references.
Exclusion criteria were
• lack of informed consent,
• known allergy to milk products
Investigational product
We compared F75 to the modified F75 (mF75) formulation (Table 1). Osmolarity was
298 mOsm/L and 232 mOsm/L for F75 and mF75, respectively. The formulations were isoca-
loric, and the reduced energy from carbohydrates was compensated by increased medium-
chain triglycerides (MCTs), while protein and micronutrient composition were unaltered.
Both formulations were manufactured by Nutriset (Nutriset, Malaunay, France) and dispensed
by trained staff according to WHO recommendations: 95 kcal/kg per day, divided into 8 feeds
per 24 hours.
Randomization and masking
Sequential study numbers were computer generated using Stata Statistical Software: Release 12
(College Station, TX: StataCorp LP) with random block sizes for each site prior to the trial. An
independent statistician was responsible for computerized sequence generation. Children
were allocated study numbers sequentially at each site using sealed numbered envelopes.
Group allocation was blinded to participants and all trial personnel, including trial
Table 1. Formulations of F75 and mF75.
% Energy Quantity: g/1,000 ml
Macronutrients F75 mF75 F75 mF75
Protein 5.3% 5.3% 9.9 9.9
Lipid 31.5% 51.7% 26.3 43.1
Carbohydrate 63.2% 43.0% 118.5 80.6
Total 100% 100% 154.7 133.6
Carbohydrate composition
Lactose 9.9% 0% 18.6 0
Sucrose 3.6% 3.6% 6.8 6.8
Maltodextrin 50% 39% 93.2 73.9
Abbreviations: F75, standard F75; mF75, modified F75.
https://doi.org/10.1371/journal.pmed.1002747.t001
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coordinators and the principal investigator. The study products were identical in appearance
and packaged in color-coded sachets.
Procedures
Children were managed in the hospital as per Malawian or Kenyan national guidelines, both
of which are based on WHO recommendations [15,16]. HIV testing by rapid antibody test was
offered to all participants according to national guidelines, with appropriate counseling, fol-
low-up tests, and referrals offered depending on results. Children were examined daily, and
clinical status was recorded on a standardized proforma during ward rounds. If a child deterio-
rated after stabilization, they were returned to the stabilization phase and received F75 or
mF75 as originally allocated. Blood and fecal samples were collected at admission and after
3 days of hospitalization.
The clinical team was blinded for the allocated formula and decided whether a child was fit
for discharge based on criteria such as being in rehabilitation phase, clinical condition, ability
to finish RUTF, and appetite level. RUTF, nutritional counseling, and follow-up in a nutrition
clinic were provided at discharge, as per standard of care at each institution.
Primary and secondary outcomes
The primary outcome was based on the purpose of F75, which is clinical stabilization, after
which a child can progress to higher protein and energy feeds to promote catch-up growth.
We therefore chose the number of days between admission and first stabilization as the pri-
mary outcome, defined as having reached the transition phase of treatment and switched to
another feed type. Stabilization was based on the WHO guideline [15]:
1. absence of any WHO “danger” or emergency signs: obstructed breathing, respiratory dis-
tress, cyanosis, shock (delayed capillary refill plus fast and weak pulse plus temperature gra-
dient), severe anemia (Hb< 5 g/dl), congestive cardiac failure, impaired consciousness,
convulsions, severe dehydration, profuse watery diarrhea or vomiting, hypothermia;
2. loss of edema (if present on admission), defined as improving from a severe +++ edema
(severe: generalized bilateral pitting edema) to ++ edema (moderate: no upper arm or
upper leg edema and no facial edema), or from ++ edema to + edema (mild: only feet/ankle
edema), or none;
3. and tolerating the full prescribed volume of F75 feeds and observed to be completing the
feeds.
Study clinicians received additional training on the WHO guidelines as well as bedside and
scenario-based training on the criteria for transition to improve standardization across sites.
In order to include children who died before stabilization in the analyses, they were classified
as “not stabilized.”
Although there is some subjectivity in determining a child’s medical condition that is
“improving,” we chose stabilization as a main outcome rather than episodes of diarrhea
because 1) it is the purpose of F75; 2) once a child switches to F100 or RUTFs, earlier transition
could conceivably result in an increase in diarrhea unrelated to mF75 or F75; 3) diarrhea is
very difficult to quantify objectively since maternal recall is not accurate in identifying episodes
or severity [25]; 4) diapers may not distinguish every stool episode, and their weight is affected
by urine; and 5) refeeding syndrome may be critical to early outcomes.
Prespecified secondary outcomes were the total number of days and number of days prior
to stabilization with
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1. diarrhea (i.e., 3 or more loose or watery stools within 24 hours),
2. receipt of rehydration fluids (ReSoMal or IV fluids),
3. signs of shock (i.e., fast and weak pulse with limb versus core temperature gradient and cap-
illary refill time > 3 seconds),
4. lower chest wall indrawing,
5. hypoxemia (i.e., fingertip SaO2 < 90% or requiring oxygen to maintain SaO2 above 90%),
6. impaired consciousness (i.e., Blantyre coma score < 4) [26],
7. symptomatic hypoglycemia (i.e., blood sugar < 3.0 mmol/l, tested only on clinical
indication),
8. vomiting,
9. congestive cardiac failure,
10. any antibiotics and second- or third-line antibiotics,
11. receiving F75 (initial stabilization plus any restabilization),
12. Nasogastric tube feeds or nonstandard feeds,
13. receiving breastmilk.
Other prespecified secondary outcomes were
1. mortality in hospital;
2. time to discharge from hospital in days;
3. the total number of days spent in the stabilization phase, including periods when children
deteriorated and returned to the stabilization phase;
4. percentage change in weight between admission and day 5;
5. serum sodium, potassium, magnesium, calcium, phosphate, and albumin at day 3 and
changes between admission and day 3;
6. stool osmotic gap and pH at day 3.
Laboratory analyses
Blood was collected at admission and day 3, from which serum was obtained and stored at −80
˚C. For analysis, samples were thawed overnight at 4 ˚C, vortexed, and centrifuged at 1,500 g
for 3 minutes. Albumin, alanine aminotransferase (ALT), creatinine, calcium, magnesium,
potassium, phosphate, sodium, and urea were batch analyzed using the P-module on a Roche
Modular (Roche, Indianapolis, United States) at a single laboratory (University Medical Cen-
tre Groningen, the Netherlands). Fecal samples were collected at both time points and stored
at −80 ˚C. Fecal biochemistry was batch analyzed only amongst patients with clinical diarrhea
in the same laboratory. These samples were thawed overnight at 4 ˚C and weighed, diluted 3.5
times with distilled water, homogenized (Precellys 24 Homogenizer, Bertin, Rockeville, USA),
and centrifuged at 16,100 g/rcf for 5 minutes. Fecal water was extracted, and osmolality was
measured by freezing point depression (Osmo Station OM-6050, Arkray, Tokyo, Japan). In
addition, sodium, potassium, and chloride were analyzed using the ISE900-module on Cobas
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8000 (Roche, Indianapolis, USA). pH was determined using a standard pH meter. The stool
osmotic gap was calculated by the equation 290 − 2 × (stool Na + stool K).
Statistical analyses
A statistical analysis plan was reviewed and approved by an independent Data and Safety Mon-
itoring Committee (DSMC) before the treatment allocation was unmasked, and the research
database was locked. The DSMC oversaw the trial and reported to the Trial Steering Commit-
tee (TSC). An interim unblinded analysis was conducted by the DSMC during the trial after
50% of participants were recruited. A recommendation to the sponsor to discontinue recruit-
ment, in all patients or in selected subgroups, would be made by the TSC on advice from the
DSMC if the data provide proof beyond reasonable doubt that one of the treatment arms is
better in terms of the primary outcome or safety guided by the Haybittle–Peto criteria. The
Haybittle–Peto boundary states that if an interim analysis shows a probability of less than
0.001 that the treatments are different, then the trial should be stopped early.
For the primary endpoint of time to first stabilization, we regarded it as essential to include
children who died before stabilization in the analysis. Therefore, the time to stabilization of
children who died was entered as “999,” ensuring that they ranked bottom in the rank sum test
and were included in the longest quartile of the IQR. An intention-to-treat analysis was con-
ducted including all available data, including from children given the wrong formula at one or
more feeds (primary endpoint evaluable) and children who withdrew or absconded, i.e., left
the hospital without notifying the medical team or were transferred prior to stabilization (pri-
mary endpoint nonevaluable). We calculated the median (IQR) time to stabilization in the 2
randomized groups and compared their distributions using a Wilcoxon rank sum test and
incidence rate ratio using Cox regression. We also conducted prespecified subgroup analyses
to assess effect modification by site, HIV antibody status, edema status, and age using likeli-
hood ratio tests. In addition, using the cmprsk R-package, we conducted competitive risk anal-
ysis to compare the cumulative incidence functions of the mutually exclusive risks of either
dying prior to stabilization or achieving stabilization. Differences in these incidence functions
indicate whether the cumulative probability of either dying before stabilization or achieving
stabilization differs between groups as treatment progresses.
For secondary outcomes, we compared the number of days with prespecified clinical fea-
tures between allocated groups using regression with a zero-inflated negative binomial distri-
bution, since many children had no days with these problems. To compare the distributions of
continuous variables, we used Student t test or Wilcoxon’s rank sum test if the variables were
skewed. We compared categorical variables between randomized groups using χ2 or Fisher’s
exact tests. Trends in proportions across ordered groups were assessed by a nonparametric test
for trend. HIV test results were analyzed with “not done” as a separate category, as some chil-
dren who died before testing or whose parents refused testing may have been more likely to
have HIV infection or exposure. Blood and stool biochemical variables between intervention
arms were compared while adjusting for site, whereas models comparing admission and day 3
included a random intercept for patients. All statistical analyses were done using either Stata
version 13.0 (StataCorp 2013, Stata Statistical Software: Release 13; College Station, TX: Stata-
Corp LP) or R statistical software version 3.4.0 [27].
Sample size
Based on prior trial experience [28], we estimated that 50% of children allocated to F75 would
stabilize by day 5, and we calculated the sample size required to demonstrate a 10% absolute
increase in percentage stabilized at day 5 to 60% in the intervention arm (equivalent to a
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hazard ratio of 1.35). With an alpha of 5% and power of 80%, the number of patients required
was 381 per arm, and to allow for 10% anticipated losses, we aimed to recruit 420 per arm.
Ethical considerations
The trial was registered at ClinicalTrials.gov, number NCT02246296. Ethical approval was
obtained from the College of Medicine Research Ethics Boards of the University of Malawi
(P.03/14/1540), the KEMRI Ethical Review Committee (SCC 2799), the Oxford Tropical
Research Ethics Committee (OXTREC 58–14), and the Hospital for Sick Children Research
Ethics Board, Toronto (1000046559).
Results
Patient characteristics
Between 4 December 2014 and 24 December 2015, 843 hospitalized children were enrolled,
418 were allocated to F75, and 425 were allocated to mF75 (Fig 1). The median age of partici-
pants was 16 months (IQR 10 to 25 months); 385 (46%) were female, 264 (31%) had kwashior-
kor, 382 (45%) had diarrhea at admission, and 179 (21%) had a positive HIV test, with 46
(5.5%) having a declined or missed HIV test. Overall, 516 (61%) were enrolled in Kenya and
327 (39%) in Malawi. Baseline clinical and demographic characteristics were similar between
randomized groups and are presented in Table 2.
Of a total of 7,098 child days of hospitalization, 2,615 were prior to stabilization, and 75/843
(8.9%) children died prior to stabilization. Nine children voluntarily withdrew from the study
prior to stabilization, and 6 absconded from the hospital (as defined above). Seven children
were transferred to another hospital, 4 of whom because of hospital closure due to a health
worker strike. Nine children (1.0%) received the wrong formula at one or more feeding times
and were included in the primary analysis.
Primary outcome
The median time to stabilization was 3 days (IQR 2–6 days) (Fig 2, Table 3, and S1 Fig), and
there was no evidence for difference in time to stabilization between randomized groups; abso-
lute difference 0.23 (95% CI −0.13 to 0.60, P = 0.59). Prespecified subgroup analyses did not
suggest effect modification by the presence of diarrhea at admission, age, edema, or site (S1
Table). There was evidence of an effect of HIV status (P< 0.0001) on both time to stabilization
and time to mortality but no interaction between HIV status and effect of allocated feeds
(P� 0.33, S2 Table).
Secondary clinical outcomes
There was no effect of the intervention on mortality before stabilization (P = 0.84) or during
hospitalization overall (P = 0.44, Table 3). As presented in S3 Table, 117 (14%) children experi-
enced a serious adverse event before stabilization without evidence of difference between ran-
domized groups (P = 0.59). Diarrhea was common; of the 416 children without diarrhea at
admission, 176 (38%) developed diarrhea in hospital. The number of days with diarrhea prior
to stabilization and during the whole hospitalization period were similar in both groups
(Table 3). There were no significant differences in the number of days with vomiting or receiv-
ing rehydration fluids (ReSoMal or IV fluids). The types of other feeds children received (non-
standard milks) and routes (nasogastric or oral) were not affected by randomized allocation,
except breast milk, which was lower in the mF75 group (P = 0.04). Hypoglycemia (<3.0
mmol/l) rarely occurred, and the number of days with an episode of hypoglycemia was not
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influenced by the intervention (Table 3). The number of days receiving antibiotics was also
not affected by the intervention and neither was the mean (±SD) percent of weight change
between admission and day 5 (3.1% ± 5.8% in nonoedematous, P = 0.78; −3.4% ± 7.1% in
oedematous patients, P = 0.63). Although uncommonly diagnosed, the incidence of clinician-
defined congestive heart failure was lower in the mF75 group (P = 0.007).
Fig 1. Numbers of children who were screened, assigned a trial group, and included in the primary analysis. Children aged 6 months to 13 years who
were admitted for complicated SAM were screened for eligibility in the participating hospitals. They were enrolled after informed consent was obtained.
SAM, severe acute malnutrition.
https://doi.org/10.1371/journal.pmed.1002747.g001
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Biochemical outcomes
Table 4 shows the serum and fecal biochemistry. There were no differences between the overall
distributions of biochemical concentrations in serum between the standard and mF75 on day
3. Hyponatremia was common, both at admission and after 3 days (Table 5), without differ-
ences between the groups, whereas hypernatremia was rare. The prevalence of abnormal
potassium concentrations was not different between the groups. Hypokalemia was frequently
Table 2. Baseline characteristics.
F75 mF75
Demographics (n = 418) (n = 425)
Age in months (median, IQR) 16 (10–26) 16 (10–25)
Female 180 (43) 205 (48)
Primary caregiver is mother 388 (93) 402 (95)
Site
Kilifi County Hospital, Kenya 92 (22) 95 (22)
Coast General Hospital, Kenya 164 (39) 165 (39)
Queen Elizabeth Central Hospital, Malawi 162 (39) 165 (39)
Nutrition
MUAC (mean, SD) 11.2 (1.4) 11.3 (1.5)
Weight-for-age Z score� (mean, SD) −4.1 (1.2) −4.0 (1.1)
Weight-for-height/length Z score� (mean, SD) −3.8 (1.1) −3.7 (1.0)
BMI Z score� (mean, SD) −4.7 (1.7) −3.9 (1.3)
Height/length-for-age Z score (mean, SD) −2.8 (1.8) −2.8 (1.7)
Edema 129 (31) 135 (32)
Currently breastfeeding 186 (45) 205 (48)
Clinical condition at admission
Signs of shock 17 (4.1) 9 (2.1)
Impaired consciousness 14 (3.4) 16 (3.8)
Severe pneumonia 106 (25) 105 (25)
Diarrhea 194 (46) 188 (44)
Temperature� 38.5 ˚C 121 (29) 123 (29)
Temperature < 36.5 ˚C 28 (6.7) 19 (4.5)
Oxygen or SaO2 < 90% 31 (7.4) 34 (8.0)
Malaria parasitemia 29 (7.0) 38 (8.9)
Chronic conditions
Tuberculosis 12 (2.9) 6 (1.4)
Cerebral palsy 62 (15) 68 (16)
Chronic cough 28 (6.7) 24 (5.7)
Sickle cell disease 1 (0.2) 1 (0.2)
Congenital or acquired heart disease 10 (2.4) 7 (1.7)
HIV antibody test
Positive 98 (23) 81 (19)
Untested 18 (4.3) 28 (6.6)
Abbreviations: F75, standard F75; mF75, modified F75; MUAC, mid-upper arm circumference.
All data are n (%) unless otherwise indicated.
�Excludes children with edema. WAZ, weight-for-age z scores; WHZ, weight-for-height z scores; and HAZ, height-
for-age z scores are calculated for children <5 years old.
https://doi.org/10.1371/journal.pmed.1002747.t002
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found but decreased in prevalence between admission and day 3, whereas hyperkalemia
increased. Hypermagnesemia was more common than hypomagnesaemia at admission, but
not on day 3, and no differences were found between the F75 and mF75 group. Hypophospha-
temia was present in 10% of children at admission, declining to 5.9% at day 3, with higher
prevalence in the mF75 group (P = 0.009).
Among children with diarrhea on day 3, when stool collection was undertaken, 88% had a
fecal osmotic gap >100 mOsm/kg, indicating osmotic diarrhea (Table 6). There were no dif-
ferences between the randomized groups in the prevalence of low <50 mOsm/kg or high
>100 mOsm/kg stool osmotic gap at day 3.
Discussion
We tested a significantly modified formulation of F75 among hospitalized children with SAM.
There was no evidence of effect on the primary outcome of time to stabilization. The median
time to stabilization was 3 days, which was shorter than anticipated, possibly due to careful
provision and timing of F75 feeds but within the range suggested by WHO guidelines [14].
Combined with the fact that there was also no evidence of differences in any of the secondary
outcomes, we conclude that an approximately 30% reduction in carbohydrate load without
lactose is not more effective than standard F75. Similarity in the primary and secondary
Fig 2. Primary endpoint, time to stabilization. Blue bars indicate the number of children who stabilized each day; the cumulative proportion stabilized
allocated to F75 is shown by the blue line and allocated to mF75 by the dashed black line. F75, standard F75; mF75, modified F75.
https://doi.org/10.1371/journal.pmed.1002747.g002
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outcomes between groups does not suggest that the result was due to a lack of statistical power.
The overall inpatient case fatality ratio of 15% was similar to estimates reported before by the
participating sites [12,28].
There is strong evidence from observational studies that carbohydrate digestion and
absorption is impaired in severely malnourished children [18,19]. Consequently, ingesting car-
bohydrates beyond the intestinal capacity for absorption can lead to osmotic diarrhea. Diar-
rhea has been associated with mortality in severely malnourished children [29,30], and cases of
osmotic diarrhea often present with clinical complications of electrolyte disturbances and
dehydration. However, there is limited evidence from intervention studies. Among children
Table 3. Primary and secondary outcomes.
Primary outcome F75 (n = 418) mF75 (n = 425) IRR (95% CI) P value
Days to stabilization, median, IQR# 3 (2–5) 3 (2–5) 1.05 (0.91, 1.22) 0.48
Secondary outcomes prior to first stabilization 1,349 child days 1,266 child days
Children who died, n (%) 36 (8.6) 39 (9.0) 0.97 (0.62, 1.52) 0.89
Children having a severe adverse event, n (%) 57 (14) 60 (14) 1.02 (0.65, 1.60) 0.92
Days Days
Diarrhea 521 469 1.03 (0.81, 1.30) 0.84
Vomiting 247 275 1.36 (0.94, 1.95) 0.10
ReSoMal treatment 593 555 0.98 (0.80, 1.24) 0.98
IV fluid treatment 71 50 0.70 (0.29, 1.70) 0.43
Signs of shock 32 19 0.79 (0.11, 1.69) 0.08
Oxygen therapy 110 70 0.87 (0.48, 1.58) 0.65
Impaired consciousness 67 58 1.03 (0.51, 2.08) 0.94
Symptomatic hypoglycemia 11 6 0.17 (0.01, 2.83) 0.22
Receiving antibiotics 1,106 1,060 0.96 (0.84, 1.09) 0.51
Receiving 2nd line antibiotics 366 294 0.83 (0.59, 1.17) 0.28
Receiving nonstandard feeds 55 36 0.58 (0.34, 1.02) 0.06
Nasogastric tube in situ 238 230 1.02 (0.72, 1.44) 0.92
Subcostal chest wall indrawing 183 159 0.86 (0.55, 1.36) 0.52
Congestive cardiac failure 25 9 0.17 (0.05, 0.61) 0.007
Receiving breastmilk 490 443 0.78 (0.61, 0.98) 0.04
Secondary outcomes during hospitalization 3,546 child days 3,553 child days
Death, n (%) 59 (14) 68 (16) 1.20 (0.82, 1.76) 0.34
Days Days
Days of hospitalization in survivors, median, IQR 8 (6–11) 8 (6–12) 1.02 (0.93, 1.12) 0.73
Days from stabilization to discharge, median, IQR 7 (5–11) 7 (5–12) 1.05 (0.94, 1.17) 0.39
Days in stabilization, including restabilization 1,610 1,650 1.09 (0.82, 1.44) 0.55
Receiving antibiotics 3,145 3,096 0.98 (0.90, 1.07) 0.70
Receiving 2nd line antibiotics 1,359 1,245 0.94 (0.80, 1.10) 0.44
Receiving nonstandard feeds 176 134 0.64 (0.38, 1.07) 0.09
Nasogastric tube in situ 345 329 1.10 (0.80, 1.51) 0.55
Abbreviations: F75, standard F75; IRR, incidence rate ratio; mF75, modified F75
Except where otherwise indicated, all data are the total number of days in which the children experienced clinical signs, and this included children who subsequently
died the counts of days with clinical signs. IRRs were obtained from site-adjusted zero-inflated negative binomial regression models.
#Differences in days to stabilization between F75 and mF75 were tested using hazard ratio from a Cox regression model adjusted for site. P values are unadjusted for
multiple comparison.
https://doi.org/10.1371/journal.pmed.1002747.t003
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with SAM, Kerpel-Fronius and colleagues gave boluses of 2–2.5 g/kg of different types of car-
bohydrates and found that lactose administration especially lowered stool pH, a marker of car-
bohydrate malabsorption [31]. These sugar boluses were in a physiological range that is
similar to a 3-hourly feed of F75 and suggested that changing lactose to sucrose might aid
absorption. Kukurozovic and colleagues evaluated the effects of different lactose-free formulas
in malnourished Australian aboriginal children presenting with diarrhea and found significant
differences in the duration of diarrhea between the different formulas, potentially related to
their osmolality [32]. The modification of energy from carbohydrates in our study was sub-
stantial (approximately 30% reduction) and suggests no linear relationship between the
amount of carbohydrates ingested and stool frequency or consistency in this population. This
finding is consistent with mF75 still exceeding a threshold for intestinal absorption among
children who had diarrhea.
Most experience on feeding children with severely impaired intestinal function has been
gained from treating short bowel syndrome, for which carbohydrates can be a limiting factor
in the ability to advance feeds, thus use of complex carbohydrates is commonly advised [33].
The carbohydrates used in the F75 formula apart from lactose are, for the most part, maltodex-
trin, which is a complex carbohydrate but shorter and with more loosely bound links than
starches. Limited evidence has suggested that starches might be beneficial in patients with
short bowel syndrome, which could also be relevant for children with SAM [34]. However, a
more radical reformulation of F75 would have to ensure supply of energy in a form that
Table 4. Biochemical differences in serum and stool between patients receiving F75 or mF75 formula.
Admission versus Day 3 F75 versus mF75
Serum, median (IQR) All Admission All Day 3 F75 Day 3 mF75 Day 3 β 95% CI df P β 95% CI df P
ALT, U/L 23 (14–44) 29 (18–53) 28 (18–53) 30 (18–53) 0.68 [−13 to 6.1] 579 0.47 6.2 (−44 to 20) 662 0.47
Albumin, g/L 34 (24–41) 32 (23–38) 32 (22–38) 32 (24–39) −0.77 [−1.1 to −0.43] 538 <0.0001 0.79 (−0.61 to 2.2) 633 0.27
Calcium, mmol/L 2.2 (2–2.3) 2.2 (2–2.3) 2.2 (2–2.3) 2.2 (2–2.3) 0.025 [−0.000044 to
0.050]
638 0.051 0.023 (−0.025 to 0.071) 634 0.35
Magnesium, mmol/L 0.87 (0.79–
0.97)
0.86 (0.77–
0.95)
0.85 (0.74–
0.93)
0.87 (0.77–
0.96)
−0.036 [−0.052 to −0.020] 672 <0.0001 0.026 (−0.00096 to
0.052)
614 0.059
Phosphate, mmol/L 1.3 (0.98–1.6) 1.5 (1.1–1.8) 1.6 (1.2–1.9) 1.5 (1.1–1.8) 0.20 [0.15 to 0.24] 555 <0.0001 −0.087 (−0.18 to 0.0072) 603 0.071
Potassium, mmol/L 4.5 (3.5–5.2) 5.3 (4.7–6.1) 5.2 (4.7–6) 5.4 (4.8–6.4) 1.8 [0.96 to 2.6] 822 <0.0001 −0.12 (−1.6 to 1.4) 685 0.88
Sodium, mmol/L 136 (132–139) 135 (132–
138)
135 (132–
138)
136 (132–
139)
−0.22 [−0.80 to 0.34] 723 0.43 0.041 (−0.79 to 0.88) 685 0.92
Creatinine, μmol/L 24 (19–32) 22 (17–28) 22 (17–28) 22 (17–29) −3.6 [−5.5 to −1.8] 633 0.0002 2.6 (−0.44 to 5.7) 623 0.094
Urea, mmol/L 2.7 (2–3.9) 2 (1.3–2.9) 2 (1.4–2.9) 2 (1.2–3) −1.0 [−1.3 to −0.79] 665 <0.0001 −0.028 (−0.35 to 0.29) 608 0.86
Fecal, median (IQR)
Chloride, mmol/kg 19 (15–30) 17 (14–22) 17 (14–23) 18 (14–22) - - - - −0.43 (−4.1 to 3.3) 80 0.82
Potassium, mmol/kg 47 (36–63) 54 (42–67) 55 (43–67) 52 (42–72) - - - - 2.7 (−5.5 to 11) 81 0.52
Sodium, mmol/kg 21 (7–42) 4 (0–10) 5.5 (0–14) 0 (0–10) - - - - −3.9 (−9.3 to 1.4) 80 0.15
Osmolarity, mOsmol/kg 354 (315–416) 357 (318–
392)
356 (315–
391)
357 (332–4
06)
- - - - 28 (−0.84 to 57) 89 0.060
Abbreviations: ALT, alanine aminotransferase; CI, confidence interval; df, degrees of freedom; F75, standard F75; mF75, modified F75.
Models comparing blood and stool biochemistry variables between groups at day 3 were adjusted for site, whereas a random intercept for patient was included when
comparing timepoints.
�Fecal biochemistry was only analyzed in children with clinical diarrhea, and comparison of admission with day 3 was not performed because of the small number and
likely high selection bias of samples when comparing admission to day 3. Coefficients (β) and 95% confidence intervals express concentration differences between
comparison groups; the reference groups were as appropriate children at admission or those receiving standard F75 formula. P values are unadjusted for multiple
comparison, significance threshold, P < 0.05.
https://doi.org/10.1371/journal.pmed.1002747.t004
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prevents hypoglycemia. We are aware of an ongoing study evaluating whether lactose-free for-
mula affects the outcome of severely malnourished children (www.isrctn.com/
ISRCTN98124592).
Diarrhea in SAM is multifactorial; infectious causes and intestinal inflammation as well as
impaired digestion of fat and protein related to exocrine pancreas and hepatobiliary dysfunc-
tion likely impact the overall nutrient absorptive capacity, and these pathways would not be
directly ameliorated by our intervention [12,35,36]. Most cases of diarrhea were osmotic in
nature rather than secretory, suggesting that bacterial infections such as enterotoxin-produc-
ing Escherichia coli or rotavirus were likely not contributing substantially to the diarrhea at day
3. We did not determine diarrhea etiology to estimate the contribution of infectious causes.
Biochemical findings suggest that refeeding syndrome was relatively uncommon on day 3
in our study. The incidence of refeeding syndrome during treatment of severely malnourished
children is not well established due to the lack of clear defining criteria and serial biochemical
measurements. The prevalence of hypophosphatemia (<0.70 mmol/l) on day 3, an indicator
of refeeding syndrome, was relatively low at 5.9% in our cohort but significantly higher in the
mF75 group, although the median serum phosphate did not differ. We found no other differ-
ences in biochemical features of refeeding syndrome. Kimutai and colleagues reported an
increase in hypophosphatemia (<1.20 mmol/l) from 6% on admission to 22% on the second
Table 5. Prevalence of abnormal blood biochemistry at admission and day 3 in patients receiving F75 or mF75 formula.
All Admissions F75 mF75 P All Day 3 F75 mF75 P
n = 683 n = 318 n = 322 n = 689 n = 340 n = 349
Low
Sodium, <135 mmol/L 278 (41%) 124 (37%) 154 (45%) 0.036 294 (43%) 152 (45%) 142 (41%) 0.32
Potassium, <3.5 mmol/L 158 (23%) 75 (22%) 83 (24%) 0.59 32 (4.6%) 12 (3.5%) 20 (5.7%) 0.21
Magnesium, <0.7 mmol/L 66 (10%) 26 (8.2%) 40 (12%) 0.091 93 (15%) 51 (17%) 42 (13%) 0.26
Phosphate, <0.7 mmol/L 63 (10%) 27 (8.7%) 36 (11%) 0.29 36 (5.9%) 8 (2.6%) 28 (9.2%) 0.0009
High
Sodium, >145 mmol/L 25 (3.7%) 13 (3.8%) 12 (3.5%) 0.84 20 (2.9%) 10 (2.9%) 10 (2.9%) 1.0
Potassium, >5 mmol/L 202 (30%) 98 (29%) 104 (30%) 0.80 417 (61%) 191 (56%) 226 (65%) 0.024
Magnesium, >1 mmol/L 120 (19%) 55 (17%) 65 (20%) 0.36 83 (13%) 30 (9.8%) 53 (17%) 0.013
Phosphate, >1.5 mmol/L 190 (30%) 97 (31%) 93 (29%) 0.66 317 (52%) 160 (53%) 157 (51%) 0.75
Abbreviations: F75, standard F75; FDR, false discovery rate; mF75, modified F75.
Data are presented as n (%) of patients with blood electrolyte values above or below normal ranges. Differences between comparison groups in the prevalence of
abnormal values were tested using Fisher’s exact test, and both uncorrected and false discovery rate (FDR) corrected P values are presented. Missing electrolyte values
are as follows: at admission: potassium, n = 13; magnesium, n = 45; phosphate, n = 52; at day 3: potassium, n = 98; magnesium, n = 77; phosphate, n = 81. P values are
unadjusted for multiple comparison, significance threshold, P< 0.05.
https://doi.org/10.1371/journal.pmed.1002747.t005
Table 6. Prevalence of low and high stool osmotic gap at admission or day 3 in patients receiving F75 or mF75 formula that had signs of clinical diarrhea.
All Admission F75 mF75 P All Day 3 F75 mF75 P
Osmotic Gap n = 112 n = 59 n = 53 n = 84 n = 52 n = 32
Low, <50 7 (6.3%) 3 (5.1%) 4 (7.5%) 0.71 1 (6.3%) 1 (1.9%) 0 (0%) 1.0
High, >100 80 (71%) 38 (64%) 42 (79%) 0.096 74 (88%) 47 (90%) 27 (84%) 0.49
Abbreviations: F75, standard F75; FDR, false discovery rate; mF75, modified F75.
Data are presented as n (%) of patients with diarrhea for which calculated stool osmotic gap values were above or below normal ranges. Differences between comparison
groups in the prevalence of abnormal values were tested using Fisher’s exact test, and both uncorrected and FDR corrected P values are presented.
https://doi.org/10.1371/journal.pmed.1002747.t006
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day of hospitalization of children with SAM [37]. A recent study in Uganda reported hypopho-
sphatemia on the second day of hospitalization in 58% of children with SAM who died and
13% in the children who survived [24]. The cutoff was much higher than in our study at 1.6
mmol/l for infants and 1.1 mmol/l in older children. In the latter study by Rytter and col-
leagues, children with diarrhea were given a rice porridge, which has a higher carbohydrate
content than F75, and although not a trial, mortality was reported to be higher in this group.
Another possible explanation for the low prevalence of severe biochemical signs of refeeding
syndrome in SAM might also be related to the observation that insulin response is impaired in
SAM children [38].
We choose to replace the carbohydrates with lipids, in particular with MCTs, for a number
of reasons. First, MCTs are more rapidly hydrolyzed in the intestinal lumen than long-chain
triglycerides, and MCTs do not require pancreatic lipase or bile for intestinal absorption.
Secondly, MCTs are more easily absorbed, as they bypass the lymphatic system. MCTs
require no or minimal carnitine to enter mitochondria, which could be beneficial if carnitine
levels are deficient. Finally, lipid malabsorption is thought not to lead to dehydration or elec-
trolyte disturbances. Despite these potential theoretical beneficial effects for critically ill mal-
nourished children, our study did not suggest that increased MCTs impact overall clinical
outcome.
Strengths of this trial are the study size; the double-blind and multicenter design, thereby
enhancing its generalizability; and it being carried out in routine practice conditions. We cap-
tured detailed daily clinical information, which gave us unique insight into clinical evolution.
There has been a long-standing debate on how to best transition children from the F75 for-
mula to RUTFs or the F100, with similar concerns about increasing carbohydrate load and the
risk of exacerbating or new onset diarrhea [15]. This study also directly informs this debate
and suggests that reducing the carbohydrate content during transition or rehabilitation might
not impact clinical outcome. There is one recent trial from our group that supports this,
although more and larger trials are needed for generalizability [39]. The main limitation of the
study is that the main outcome, stabilization with transition to the next phase of therapy, was
based on WHO guidelines, comprising clinical evidence of recovery from acute illness as well
as metabolic stabilization evidenced by recovery of appetite. We chose this main outcome as
opposed to diarrhea for a number of reasons. Firstly, stabilization is the purpose of using F75
milk formula. Diarrhea is difficult to assess objectively, particularly in our setting. Maternal
recall is not accurate in identifying diarrhea or assessing its severity [25]. Alternatively, the sys-
tematic observation of diapers could have been introduced; however, considering the added
clinical load, the implementation in our setting was not feasible. For example, determining
stool frequency would have required very frequent checks over 24-hour periods by already
short-staffed research nurses. Importantly, the lack of improvement in individual daily clinical
signs in our trial strongly suggests that the similar results obtained from the different formula-
tions on the primary outcome is not due to subjective variation in the clinical decision of tran-
sitioning a child from the stabilization phase.
In conclusion, using a reduced-carbohydrate, lactose-free F75 did not improve the time to
stabilization or other clinical outcomes of children with complicated severe malnutrition. The
results support the ongoing use of the current F75 formulation and suggest that empiric use of
lactose-free formula for children with diarrhea is not needed. It is important to explore
whether our findings are replicated in an Asian context, as there could be Africa/Asia differ-
ences in SAM and associated infections. Finally, the carbohydrate content and composition
are not the only determinants of F75 efficacy, and other aspects of treatment are also likely to
be important.
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